about
Cannulation strategies for percutaneous extracorporeal membrane oxygenation in adultsPharmacological therapy for patients with chronic thromboembolic pulmonary hypertensionFuture perspectives in pulmonary arterial hypertensionAn epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan.Inhaled iloprost for severe pulmonary hypertension.Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries.Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updatesImatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.Definitions and diagnosis of pulmonary hypertension.Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry.2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).Diagnosis and assessment of pulmonary arterial hypertension.Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the InLow frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertensionLack of association between angiotensin converting enzyme (ACE) genotype, serum ACE activity, and haemodynamics in patients with primary pulmonary hypertension.Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry.Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias.Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses.Updated evidence-based treatment algorithm in pulmonary arterial hypertension.The search for an oral prostanoid to treat pulmonary arterial hypertension continues. Are we getting any closer?Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice.Cologne Consensus Conference on pulmonary hypertension.Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011.The changing landscape of pulmonary arterial hypertension and implications for patient care.[Extracorporeal membrane oxygenation : Principles and medical indications].Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).Medical management of chronic thromboembolic pulmonary hypertension.A global view of pulmonary hypertension.Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study.Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study.State of the Art: Bridging to lung transplantation using artificial organ support technologies.Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum.Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study.Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital substraction angiography.Balloon pulmonary angioplasty: applicability of C-Arm CT for procedure guidance.
P50
Q26775429-20304E48-23E3-4FC2-8364-944671448EB7Q27003262-DC75FED7-4C84-4293-9603-239B334012C1Q28075445-9E6FAB08-041A-430B-ADD3-C365938B87E7Q30235038-FEC2EECC-1E1A-4CCE-A9CB-C232CD1D7EFFQ33147955-83E9E81B-AB7D-41C6-97FC-5606AFF6A32AQ33800429-F041511C-EE5A-4B7C-BB01-1E27C776700AQ33965904-A8EE2099-09E8-485A-98AC-57872AEDD244Q34035546-C26EA063-CB28-4579-BE45-3AF3AC75A6FEQ34393150-D0FC72ED-D682-4F8B-B39A-8CEE62505DB3Q34402406-2DCE263E-1584-4902-A775-A61F20D6F031Q34419686-D3F3514D-8B19-4421-B2DB-23BD0093C37BQ34491530-397FA0E4-FA05-41DE-A881-9E03528B6A98Q34641890-C329EF55-1940-4C55-A00D-C861CEB651F9Q34666291-F905B06E-7210-41FE-AAD7-F50D298F6667Q34989034-2A368B71-46C8-4B94-9903-D40FB6B10D35Q34999923-43762634-DE7A-47E4-99BB-024C69EB87B7Q35444290-5877564E-38F5-46BC-87E7-5FA1E410EF38Q35585175-3B139F1C-516C-4B3E-82F9-C6928DA7B115Q35801391-16217705-CC33-4431-892A-38A67C021FB2Q35858996-2A025700-4A16-4C39-897A-5D7A677995A1Q35986352-74889B1C-294C-4C35-8182-4648E0419AB2Q36590361-B9B6A1C6-877B-439E-967C-93022471E4EAQ36939543-676499FE-6CC1-49AB-957E-A3ADD92B7F8CQ37380040-A2C15A10-A7E2-4BC0-9562-6509018A2463Q37726787-E0EFD575-8A43-492B-B062-73B29037EA37Q37973535-907D9256-B771-4AA2-9CB4-0CB0B6ED8253Q37973539-F654D83F-746C-42C7-88BB-CDE1E0D2D9F1Q38274917-C4384898-B286-4191-9EA7-F7D9F19A8534Q38378895-9F17D054-1A59-4A05-BFAE-B4B8F748D2CBQ38443744-28F65D02-0975-4B17-8B25-964D1577951FQ38737921-1662AB2A-1BB3-4052-90D5-788A6B7CD17DQ38774437-1A6F1E23-CEA1-40CE-9A4F-C74A1C010425Q38801646-E13E44CC-80F0-4534-813A-9D952A4CF7E5Q38826223-5D44148E-200C-4713-BFB3-2569C00F22E0Q38964876-97D7ED83-83CD-4C7C-9FA2-F13C4DAB9473Q39028786-D3DEC3F6-B908-4BD9-ADAD-AC46401027BAQ39575243-990CA545-91EE-48FD-858C-A7A28DC64C4EQ39695915-4785D00E-11B7-44FF-913F-1D4B19C510DEQ39845589-225532A7-B171-444F-BDA6-EE72FAB7C6CCQ39976170-2A7CB7D3-214A-4915-A20A-D0B15498A07E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Marius M Hoeper
@ast
Marius M Hoeper
@en
Marius M Hoeper
@es
Marius M Hoeper
@sl
type
label
Marius M Hoeper
@ast
Marius M Hoeper
@en
Marius M Hoeper
@es
Marius M Hoeper
@sl
prefLabel
Marius M Hoeper
@ast
Marius M Hoeper
@en
Marius M Hoeper
@es
Marius M Hoeper
@sl
P214
P244
P106
P21
P213
0000 0000 2068 5212
P214
P244
nb2013000393
P31
P496
0000-0001-9086-2293
P569
1963-01-01T00:00:00Z
P735
P7859
lccn-nb2013000393